Article (Scientific journals)
Cabergoline and the risk of valvular lesions in endocrine disease.
Lancellotti, Patrizio; Livadariu, E.; Markov, M. et al.
2008In European Journal of Endocrinology, 159 (1), p. 1-5
Peer Reviewed verified by ORBi
 

Files


Full Text
1.pdf
Publisher postprint (100.48 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Adult; Aged; Cross-Sectional Studies; Dopamine Agonists/adverse effects/therapeutic use; Echocardiography; Endocrine System Diseases/drug therapy; Ergolines/adverse effects/therapeutic use; Female; Heart Valve Diseases/chemically induced/pathology; Humans; Male; Middle Aged; Mitral Valve/drug effects/pathology; Mitral Valve Insufficiency/chemically induced/pathology; Risk Factors
Abstract :
[en] AIMS: The cardiac valvular risk associated with lower exposure to cabergoline in common endocrine conditions such as hyperprolactinemia is unknown. METHODS AND RESULTS: We performed a cross-sectional, case-control echocardiographic study to assess the valvular status in 102 subjects receiving cabergoline for endocrine disorders and 51 matched control subjects. Cabergoline treatment ranged from 12 to 228 months, with a cumulative dose of 18-1718 mg. Valvular regurgitation was equally prevalent in both groups and was almost exclusively mild. Two cabergoline-treated subjects had moderate mitral regurgitation; there was no relationship between cabergoline dose and the presence or severity of mitral valve regurgitation (P=NS). Mitral valve tenting area was significantly greater in the cabergoline group when compared with the control subjects (P=0.03). Mitral valve leaflet thickening was observed in 5.9% of cabergoline-treated subjects; no relationship with the cumulative cabergoline dose was found. No patient had aortic or tricuspid valvular restriction. CONCLUSION: No significantly increased risk of clinically relevant cardiac valve disorders was found in subjects treated with long-term cabergoline therapy at the doses used in endocrine practice. While exposure to cabergoline appears to be safe during low-dose long-term therapy, an association with subclinical changes in mitral valve geometry cannot be completely excluded.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Lancellotti, Patrizio  ;  Centre Hospitalier Universitaire de Liège - CHU > Cardiologie
Livadariu, E.
Markov, M.
Daly, Adrian  ;  Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Burlacu, M. C.
Betea, Daniela ;  Centre Hospitalier Universitaire de Liège - CHU > Endocrinologie clinique
Pierard, Luc ;  Centre Hospitalier Universitaire de Liège - CHU > Cardiologie
Beckers, Albert ;  Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Language :
English
Title :
Cabergoline and the risk of valvular lesions in endocrine disease.
Publication date :
July 2008
Journal title :
European Journal of Endocrinology
ISSN :
0804-4643
eISSN :
1479-683X
Publisher :
BioScientifica Ltd, Bristol, United Kingdom
Volume :
159
Issue :
1
Pages :
1-5
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 12 March 2010

Statistics


Number of views
156 (11 by ULiège)
Number of downloads
222 (5 by ULiège)

Scopus citations®
 
101
Scopus citations®
without self-citations
95
OpenCitations
 
84

Bibliography


Similar publications



Contact ORBi